Correlation Of EUS-SWQ And Liver Fibrosis Pathology In Chronic Liver Disease (EUS-SWQ-202601)
EU-ME3 Endoscopic Ultrasound Shear Wave Quantification (EUS-SWQ) for Evaluating Liver Fibrosis and Histopathology in Patients With Chronic Liver Disease
The goal of this clinical study is to learn whether the Olympus EU-ME3 endoscopic ultrasound shear wave quantification (EUS-SWQ) function can accurately diagnose and grade liver fibrosis in patients with chronic liver disease. It will also learn about the safety and measurement success rate of EUS-SWQ.
The main questions it aims to answer are:
How closely do EUS-SWQ measurements match liver fibrosis stages determined by liver biopsy (the reference standard)? Does EUS-SWQ correlate better with liver biopsy results than FibroScan? How safe is EUS-SWQ and how often can successful measurements be obtained? Researchers will compare EUS-SWQ results with liver biopsy pathology (METAVIR F0-F4) and with FibroScan results to evaluate its diagnostic value.
Participants will:
Be adults with chronic liver disease who are scheduled to undergo a clinically indicated liver biopsy Undergo an EUS-SWQ examination as part of the study Have their liver stiffness measured by both EUS-SWQ and FibroScan for comparison Be monitored for any discomfort or adverse events related to the procedures A total of 65 participants will take part in this prospective, single-center, post-market clinical study.
Visão geral do estudo
Status
Tipo de estudo
Inscrição (Estimado)
Contactos e Locais
Contato de estudo
- Nome: Baiwen Li, MD
- Número de telefone: 86-21-37798480
- E-mail: muzibowen@126.com
Locais de estudo
-
-
-
Shanghai, China
- Recrutamento
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Método de amostragem
População do estudo
Descrição
Inclusion Criteria:
- Age ≥ 18 years and ≤ 80 years.
- Patients with clinical indications scheduled to undergo liver biopsy (EUS-guided) for the evaluation of liver lesions. Chronic liver disease meeting criteria for biopsy includes:Hepatitis B；Fatty liver disease；Autoimmune hepatitis；Other chronic liver diseases of unknown etiology that would benefit from liver biopsy
- Planned to undergo EUS-SWQ and FibroScan examinations prior to biopsy.
- Willing to provide and sign written informed consent.
Exclusion Criteria:
- Patients unable to tolerate endoscopic procedures.
- Patients with contraindications to endoscopy or anesthesia.
- Coagulopathy (platelet count < 50×10⁹/L, PT > upper limit of normal by 3 seconds).
- Patients with severe underlying diseases of the respiratory, cardiovascular, cerebrovascular, digestive, or hematologic systems, as well as those with psychiatric disorders.
- Patients with surgically altered anatomy that precludes adequate EUS imaging of the hepatic parenchyma.
- Patients with imaging findings suggestive of malignant liver tumors.
- Pregnant or lactating women.
- Patients with decompensated cirrhosis (gastrointestinal bleeding, ascites, encephalopathy).
- Patients who refuse to participate in the clinical study.
- Any other conditions deemed inappropriate by the investigator.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
Coortes e Intervenções
Grupo / Coorte |
|---|
|
One cohort of 65 adult patients with chronic liver disease who are scheduled to undergo clinically i
Sixty-five patients with chronic liver disease who are scheduled to undergo clinically indicated liver biopsy.
Only clinically indicated examinations including EUS-SWQ, FibroScan, and liver biopsy will be performed.
No experimental drug or device intervention is administered in this study.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Correlation between EUS-SWQ measurements and METAVIR liver fibrosis staging
Prazo: 2 weeks after the intervention
|
To assess the correlation between EUS-SWQ measurements and liver fibrosis pathology stages (METAVIR F0-F4) using liver biopsy as the reference standard.
|
2 weeks after the intervention
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Comparison of correlation with liver fibrosis between EUS-SWQ and FibroScan
Prazo: At baseline
|
To compare the correlation of EUS-SWQ and FibroScan measurements with histologically confirmed liver fibrosis stages.
|
At baseline
|
|
Safety and measurement success rate of EUS-SWQ
Prazo: At baseline
|
To evaluate the safety and technical success rate of EUS-SWQ measurement in patients with chronic liver disease.
|
At baseline
|
Colaboradores e Investigadores
Investigadores
- Investigador principal: Baiwen Li, MD, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- SH1HY-EUS-SWQ-20260123
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
produto fabricado e exportado dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .